- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00147147
Randomized Trial of Adjuvant Chemotherapy With Cisplatin Followed by UFT in Serosa-positive Gastric Cancer (JCOG9206-2)
Randomized Trial of Adjuvant Chemotherapy With Cisplatin Followed by Oral Fluorouracil (UFT) in Serosa-positive Gastric Cancer (JCOG9206-2)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Purpose: To evaluate the survival benefit of adjuvant chemotherapy after curative resection in serosa-positive gastric cancer patients, a multicenter phase III clinical trial was conducted by 13 participating centers in Japan. Methods: From January 1993 to March 1998, 268 patients were randomized to either adjuvant chemotherapy (135 pts) or surgery alone (133 pts). The chemotherapy comprised intraperitoneal cisplatin 70 mg/m2 before closing the abdomen, and after surgery intravenous cisplatin 70 mg/m2 (day 14) and 5-fluorouracil (5-FU) 700 mg/m2 daily (day 14-16), and oral FU (UFT) 267 mg/m2 daily from 4 weeks after surgery for the next 12 months. The primary endpoint was overall survival. Relapse-free survival and the site of recurrence were secondary endpoints.
Comparison: gastrectomy with D2 or greater lymph node dissection versus gastrectomy with adjuvant chemotherapy after curative resection in serosa-positive gastric cancer patients.
Study Type
Enrollment
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Tokyo
-
Chuo-ku, Tokyo, Japan, 104-0045
- Gastric Surgery Division, National Cancer Center Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Curative operation with D2 or greater lymph node dissection
- Histologically proven gastric adenocarcinoma
- Macroscopically serosa-positive (T3-4)
- No metastases to level 3 - 4 lymph nodes station (N0-2)
- 75 years or younger
- Negative peritoneal lavage cytology
- Adequate organ function WBC >=4000/mm3,Hb >=11.0g/dl,Plt >=100.000/mm3,AST/ALT, T.Bil, BUN, Creatinine <=2.5 x Normal Upper Limit,Creatinine clearance <=70 ml/min
- Written informed consent
Exclusion Criteria:
- Prior chemotherapy or radiotherapy
- Synchronous or metachronous malignancy in other organs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Overall survival
|
Secondary Outcome Measures
Outcome Measure |
---|
Relapse-free survival
|
the site of recurrence
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Hiroshi Furukawa, MD, PhD, Sakai Municipal Hospital
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- JCOG9206-2
- C000000067
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Neoplasm
-
First Affiliated Hospital Xi'an Jiaotong UniversityCompletedGastric Soft Tissue NeoplasmChina
-
Basaksehir Cam & Sakura Şehir HospitalCompletedGastric Cancer | Gastric Neoplasm | Gastric Cancer StageTurkey
-
Ukrainian Society of Clinical OncologyRecruitingStomach Cancer | Gastric Cancer | Gastric Adenocarcinoma | Gastrointestinal Cancer | Gastroesophageal Junction Adenocarcinoma | Advanced Gastric Adenocarcinoma | GastroEsophageal Cancer | Stomach Neoplasm | Gastric Neoplasm | Advanced Gastric Carcinoma | Advanced Gastroesophageal Junction AdenocarcinomaUkraine
-
Seoul National University HospitalCompletedGastric Cancer | Metachronous Neoplasm | Gastric Neoplasm | Aberrant DNA Methylation
-
Fondazione Policlinico Universitario Agostino Gemelli...Recruiting
-
Chinese University of Hong KongChangi General Hospital; Kosin University Gospel Hospital; Shizuoka Cancer Center and other collaboratorsCompletedEarly Gastric Cancer | Gastric NeoplasmJapan, Singapore, Korea, Republic of, Hong Kong
-
Asan Medical CenterUnknown
-
Kosin University Gospel HospitalInje UniversityUnknownGastric NeoplasmsKorea, Republic of
-
Weill Medical College of Cornell UniversityUnknownNeoplasms | Gastrointestinal Neoplasms | Gastric Cancer | Esophageal Neoplasms | Gastrointestinal Disease | Colon Polyp | Stomach Neoplasm | Gastric Neoplasm | Duodenal Neoplasms | Colon Neoplasm | Gastric Polyp | Duodenal Polyp | Stomach PolypUnited States
-
University of Rome Tor VergataCompletedGastric Cancer | Surgery | Gastric Neoplasm | Digestive Cancer | Laparoscopic
Clinical Trials on Gastrectomy with D2 or greater lymph node dissection
-
Yonsei UniversityRecruitingGastric CancerKorea, Republic of
-
Seoul National University Bundang HospitalRecruitingGastric Cancer | Gastric AdenocarcinomaKorea, Republic of
-
Sohag UniversityNot yet recruiting
-
National Health Research Institutes, TaiwanCompleted
-
Peking UniversityThe First Affiliated Hospital with Nanjing Medical University; Zhejiang Cancer... and other collaboratorsRecruiting
-
N.N. Petrov National Medical Research Center of...Active, not recruitingColonic Neoplasms MalignantRussian Federation
-
G.V. Bondar Republican Cancer CenterI.M. Sechenov First Moscow State Medical University; Donetsk National Medical...Active, not recruiting
-
Shanghai Pulmonary Hospital, Shanghai, ChinaRecruitingLung AdenocarcinomaChina
-
Shanghai Pulmonary Hospital, Shanghai, ChinaRecruiting
-
Southwest Hospital, ChinaThe First Affiliated Hospital of Nanchang University; Sun Yat-sen University; Chinese PLA General Hospital and other collaboratorsUnknown